Monitor the Guggenheim fireside chat replay for any incremental commentary on forazapadin clinical trial progress or FSHD Phase 2 initiation timing, but this filing itself contains no new information to trade on.
Price Chart
Executive Summary
Satellos Bioscience announced management participation in two upcoming investor conferences (Guggenheim Healthcare Innovation Conference on Nov 9 and Jefferies Global Healthcare Conference on Nov 18-19). This is a routine investor relations activity with no new clinical data, financial results, or material corporate developments disclosed.
Key Facts
- Management to present at Guggenheim 3rd Annual Healthcare Innovation Conference on Nov 9, 2026 in Boston
- Management to attend Jefferies Global Healthcare Conference on Nov 18-19, 2026 in London
- Fireside chat at Guggenheim conference will be webcast with replay available on company website
- No new clinical data, financial results, or material business developments announced
Financial Impact
No financial impact — routine conference participation with no material disclosures
Risk Factors
- No material information disclosed — stock may be unaffected by this filing
- Forward-looking statements about clinical trials and regulatory approvals carry inherent execution risk
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006724 |
| Document: f6k_102026.htm | 0001171843-26-006724 |
| Document: 0001171843-26-006724-index-headers.html | 0001171843-26-006724 |
| Document: 0001171843-26-006724-index.html | 0001171843-26-006724 |
| Document: 0001171843-26-006724.txt | 0001171843-26-006724 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers